Work related symptoms in eyes, nose, lower airways, and airways (nose or lower airways, or both) and estimated effects (OR (95% CI)) of metabolites, antibodies and lung function in 152 workers, potentially exposed to sprayed or heated polyurethane glue
| Biomarker4-150 | Work related symptoms | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| None Median | Eyes (n=21) | Nose (n=32) | Lower airways (n=17) | Airways (n=40) | |||||||||||
| Median | OR (95% CI | Median | OR (95% CI) | Median | OR (95% CI) | Median | OR (95% CI) | ||||||||
| P-MDX4-151 | 0.26 | 0.17 | 0.60 (0.22 to 1.6)4-154 | 0.38 | 0.88 (0.38 to 2.0)4-154 | 0.57 | 1.0 (0.35 to 3.1)4-154 | 0.48 | 0.98 (0.45 to 2.2)4-154 | ||||||
| U-MDX4-152 | LM | LM | 0.80 (0.17 to 3.8) | LM | 2.2 (0.76 to 6.6) | LM | 4.2 (1.3 to 14) | LM | 3.7 (1.3 to 10) | ||||||
| P-2,4-TDX4-152 | LM | LM | 0.94 (0.25 to 3.5) | LM | 0.72 (0.23 to 2.3) | LM | 1.8 (0.53 to 6.1) | LM | 1.2 (0.46 to 3.2) | ||||||
| U-2,4-TDX4-152 | LM | 0.20 | 1.3 (0.50 to 3.2) | 0.20 | 1.3 (0.61 to 2.9) | LM | 0.57 (0.20 to 1.6) | LM | 1.0 (0.49 to 2.1) | ||||||
| P-2,6-TDX4-152 | LM | LM | 1.3 (0.25 to 6.9)4-154 | LM | 0.89 (0.18 to 4.4) | LM | 6.4 (1.6 to 26) | LM | 2.9 (0.80 to 11) | ||||||
| U-2,6-TDX4-152 | LM | LM | 0 | LM | 0 | LM | 3.4 (0.61 to 19) | LM | 1.1 (0.21 to 5.9) | ||||||
| S-IgG-MDI4-153 | 0.10 | 0.10 | 0.69 (0.24 to 2.0)4-154 | 0.12 | 2.4 (1.1 to 5.3) | 0.13 | 2.6 (0.94 to 7.3) | 0.12 | 2.6 (1.2 to 5.5) | ||||||
| S-IgG-TDI4-153 | 0.12 | 0.12 | 0.48 (0.16 to 1.5)4-154 | 0.15 | 1.7 (0.77 to 3.9) | 0.13 | 1.6 (0.56 to 4.4) | 0.14 | 1.7 (0.81 to 3.7) | ||||||
| S-IgG-HDI4-153 | 0.13 | 0.16 | 2.2 (0.64 to 7.6) | 0.17 | 1.2 (0.35 to 3.9) | 0.22 | 1.8 (0.45 to 7.0) | 0.21 | 2.1 (0.75 to 6.1) | ||||||
| S-IgE-MDI4-153 | 0 | 0 | — | 0 | — | 0 | — | 0 | — | ||||||
| S-IgG4-151 | 13 | 13 | 0.66 (0.24 to 1.8)4-154 | 15 | 2.1 (0.95 to 4.7) | 15 | 2.2 (0.76 to 6.2) | 15 | 1.9 (0.93 to 4.1) | ||||||
| S-IgM4-151 | 1.2 | 1.6 | 3.9 (1.3 to 11) | 1.4 | 1.7 (0.75 to 4.0)4-154 | 1.6 | 4.1 (1.3 to 13) | 1.4 | 2.6 (1.2 to 5.5) | ||||||
| S-IgA4-151 | 2.1 | 2.0 | 1.69 (0.26 to 1.8) | 2.2 | 0.94 (0.43 to 2.1) | 2.3 | 1.2 (0.46 to 3.4) | 2.2 | 0.97 (0.47 to 2.0) | ||||||
| S-IgE4-151 | 20 | 20 | 1.0 (0.40 to 2.6) | 20 | 0.74 (0.34 to 1.6) | 36 | 1.5 (0.54 to 4.2) | 22 | 1.0 (0.49 to 2.1) | ||||||
| VC4-151 | 92 | 95 | — | 95 | 0.79 (0.36 to 1.7) | 97 | 0.54 (0.19 to 1.5) | 95 | 0.80 (0.38 to 1.7) | ||||||
| FEV1 4-151 | 96 | 100 | — | 99 | 0.73 (0.33 to 1.6) | 104 | 0.21 (0.06 to 0.77) | 100 | 0.60 (0.29 to 1.3) | ||||||
↵4-150 P-MDX and U-MDX=metabolites of 4,4′-diphenylmethane diisocyanate (MDI), P-2,4-TDX and U-2,4-TDX and P-2,6-TDX and U-2,6-TDX=metabolites of 2,4-toluene diisocyanate and 2,6-toluene diisocyanate (TDI; μg/l) in plasma and urine; S-IgG-MDI, S-IgG-TDI, S-IgG-HDI, and S-IgE-MDI=specific serum IgG (A) and IgE (%binding) antibodies against MDI, TDI, and hexamethylene diisocyanate; S-IgG, S-IgM, S-IgA, S-IgE=total serum IgG, IgM, IgA (g/L), and IgE (kU/l) antibodies; VC=vital capacity, FEV1=forced exspiratory volume in one second (% predicted); LM=limit of measurement=⩽0.05 μg/l. Clerks had no work related symptoms.
↵4-151 Dichotomised at median value.
↵4-152 Dichotomised at the limit of measurement.
↵4-153 Dichotomised into positive and negative values.
↵4-154 Adjusted for age and sex.